Blog

Brookings Institution Report Calls For Broad Reforms in Marijuana Research Policy

Oct 23, 2015

Brookings Institution, DEA, Drug Enforcement Administration, Federal, Grace Wallack, John Hudak, rescheduling


Early this week, the Brookings Institution released a report titled 'Ending the U.S. government's war on medical marijuana research', which analyzes the ways in which the federal government hinders effective research, and how these policies could be changed.logo_brookings_-axd_

The federal government is stifling medical research in a rapidly transforming area of public policy that has consequences for public health and public safety. As medical marijuana becomes increasingly accessible in state-regulated, legal markets, and as others self-medicate in jurisdictions that do not allow the medical use of cannabis, it is increasingly important that the scientific community conduct research on this substance. However, statutory, regulatory, bureaucratic, and cultural barriers have paralyzed science and threatened the integrity of research freedom in this area. It is time for the federal government to recognize the serious public policy risks born from limited medical, public health, and pharmaceutical research into cannabis and its use.
The report specifically argues that simply rescheduling marijuana will not be sufficient to remove barriers to scientific study, and that broader reforms are needed. Currently, marijuana is considered a Schedule I drug under federal law, and all research must be approved by the Drug Enforcement Administration.

You can read the full report here.